On April 22, 1999, Takahashi, Kanji; Sugiura, Tsuneyuki published a patent.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of aminobutanoic acid derivatives as inhibitors of matrix metalloproteinases. And the patent contained the following:
Aminobutanoic acid derivatives represented by general formula (I) and salts thereof [wherein R1 = CO2R10, CONHOR10, CONHNHR10, (CH2)nSR50, Y-P(:O)(OR51)2; R10 = H, C1-8 alkyl, Ph, phenyl- or C1-8 alkoxy-C1-8 alkyl, PhO2C, PhCH2O2C, C1-8 alkoxycarbonyl; wherein n = 0-3; R50 = H, C1-8 alkyl, C1-8-alkyl-carbonyl, PhCO, SH, C1-8 alkylthio, SPh; R51 = H, C1-8 alkyl, Ph; Y = single bond, CH2, O; R2-R7 = H, C2-8 alkenyl, (un)substituted SH, OH, or NH2, CO2H, C1-8 alkyl-carbonyl, C1-8 alkoxy-carbonyl, (un)substituted carbocyclyl or heterocyclyl, (un)substituted C1-8 alkyl or C2-8 alkenyl; or R3 and R4 or R5 and R6 together represents C1-8 alkylene; or R2 and R3, R4 and R5, or R6 and R7 together represent C2-8 alkylene; when R8 = H, (un)substituted C1-8 alkyl, or C1-8 alkoxy-carbonyl, R9 = (un)substituted carbocyclyl; or when R8 = (un)substituted carbocyclyl or heterocyclyl, R9 = (un)substituted C1-8 alkyl or C1-8 alkoxy, (un)substituted carbocyclyl; M = C1-8 alkylene; J = single bond, O, S, NH, C1-8 alkyl-N] are prepared and claimed. Also claimed are matrix metalloproteinases containing I as the active ingredients and drugs containing I as the active ingredients for the prevention and/or treatment of rheumatism, osteoarthritis, pathol. bone resorption, osteoporosis, periodontal diseases, interstitial nephritis, arteriosclerosis, pulmonary emphysema, hepatic cirrhosis, corneal injury, diseases due to metastasis and infiltration of cancer cells or proliferation thereof, autoimmune diseases (such as Crohn’s disease and Sjogren’s disease), diseases due to transmigration of white blood cells or infiltration thereof, neovascularization, multiple sclerosis, aortic aneurysm, or endometritis. For example, the title compound (II) showed IC50 of 26 nM against human stromelysin. A table and an ampule formulation containing II were described. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate
The Article related to antiarteriosclerotics, antirheumatic agents, antitumor agents, aortic aneurysm, autoimmune disease, bone resorption, cirrhosis, corneal injury, crohn disease, endometritis, interstitial nephritis, leukocyte, metastasis inhibitors, multiple sclerosis, neovascularization, osteoarthritis, osteoporosis, periodontal disease and other aspects.Quality Control of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics